ArticleJournal of translational medicine2026
IGF2BP2-driven serine metabolism promotes the progression of thyroid carcinoma via m
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThyroid cancer (TC) is one of the most common malignant tumors of the endocrine system, and patients with advanced and metastatic TC have a poor prognosis. Serine metabolism is an important component of tumor cell metabolic reprogramming. However, the molecular mechanism underlying the upregulation of serine metabolism in TC remains poorly understood.
methodsImmunohistochemistry was performed to observe the expression of IGF2BP2 and its target molecules in TC and adjacent tissues. RNA interference and lentivirus infection of TPC-1 and 8505 C cells were used to downregulate and overexpress key molecules, respectively. CCK8, colony formation, EdU incorporation, transwell migration and invasion, scratch wound-healing and flow cytometry assays were performed to detect the changes in cell function among the different groups. LC‒MS was used to detect serine and related metabolites in TC cells. Transcriptome sequencing, RIP, m
resultsWe observed high expression of IGF2BP2 in TC tissues, and its expression increased with the tumor stage and was associated with a poor prognosis. The inhibition of IGF2BP2 suppressed proliferation, invasion, migration and serine synthesis and metabolism in TC cells. Additionally, supplementation with serine partially rescued the proliferation defect in IGF2BP2-knockdown cells. RNA-seq indicated that PHGDH is a target of IGF2BP2, and its expression was positively correlated with IGF2BP2 expression in TC. Moreover, RIP, m
conclusionsOur results further reveal the pathogenesis of TC and provide new insights for controlling the progression of TC from the perspective of tumor metabolism in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.